Repros Therapeutics Inc. files shelf registration
Repros Therapeutics Inc. announced today that it has filed a Form S-3 shelf registration statement with the Securities and Exchange Commission for up to 6,282,052 shares of common stock.
OncoGenex Pharmaceuticals, Inc. announced today that it has filed a shelf registration statement on Form S-3 with the US Securities and Exchange Commission and an MJDS prospectus under the multi-jurisdictional disclosure system in the Province of British Columbia.